H.C. Wainwright analyst Andrew Fein maintained a Buy rating on BELLUS Health (BLU – Research Report) today and set a price target of $16.00. The company's shares closed last Tuesday at $9.75, close to its 52-week high of $11.10. According to TipRanks.com, Fein is ranked 0 out of 5 stars with an average return of -15.8% and a 34.7% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics. Currently, the analyst consensus on BELLUS Health is a Strong Buy with an average price target of $16.00.
https://www.tipranks.com/news/blurbs/h-c-wainwright-believes-bellus-health-blu-wont-stop-here-2?utm_source=advfn.com&utm_medium=referral
Blue Chip Value Fund, Inc. (NYSE:BLU)
Historical Stock Chart
From Mar 2023 to Apr 2023 Click Here for more Blue Chip Value Fund, Inc. Charts.
Blue Chip Value Fund, Inc. (NYSE:BLU)
Historical Stock Chart
From Apr 2022 to Apr 2023 Click Here for more Blue Chip Value Fund, Inc. Charts.